New medicine for atopic dermatitis!

AbbVie recently announced the evaluation of the oral JAK1 inhibitor Rinvoq (upadacitinib, upatinib) and the subcutaneous injection preparation Dupixent (Chinese trade name: dabital, generic name: dupilumab) The results of the head-to-head Phase 3b Heads Up study (NCT03738397) in adult patients with moderate to severe atopic dermatitis (AD) have been published in the international medical journal "JAMA Dermatology"

The results show that Rinvoq has an efficacy advantage compared with Dupixent in terms of the primary endpoint and all secondary endpoints

Rinvoq is an oral, once-a-day, selective and reversible JAK inhibitor.

The Heads Up study was carried out in adult patients with moderate to severe AD who are suitable for systemic treatment, and evaluated the efficacy and safety of Rinvoq (30 mg, orally, once a day) and Dupixent (300 mg, subcutaneously, once a week) as monotherapy Sex

The results published in JAMA Dermatology extend the previously published top-line results.

In addition, during the 16 weeks of treatment, Rinvoq was statistically significantly higher than Dupixent in terms of all secondary endpoints, including additional skin lesion removal and antipruritic measures

In this study, the safety of Rinvoq was consistent with that observed in 3 key Phase 3 studies (Measure Up 1, Measure Up 2, AD Up)

Heads Up study results

Atopic dermatitis (AD) is a common, chronic, recurrent, and inflammatory skin disease that is manifested by repeated cycles of itching and scratching, causing pain and cracking of the skin

Rinvoq is an oral, once-daily, selective and reversible JAK inhibitor

Currently, Rinvoq's application for new indications for the treatment of AD is under review by the US FDA and EU EMA, specifically: treatment of adult patients with moderate to severe AD (15mg and 30mg, once a day) and adolescent patients (15mg, once a day)

In the United States, the FDA has delayed the review of Rinvoq's treatment of PsA, AS, and AD because the agency is investigating the safety of JAK inhibitor drugs

The chemical structure of upadacitinib (picture source: medchemexpress.

The active pharmaceutical ingredient of Rinvoq is upadacitinib, which is an oral selective and reversible JAK1 inhibitor discovered and developed by AbbVie.

Currently, Rinvoq treats ulcerative colitis (UC), rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), Crohn’s disease (CD), atopic Phase III clinical studies of sexual dermatitis (AD) and giant cell arteritis (GCA) are underway

The industry is very optimistic about Rinvoq's business prospects

Humira is the world's first approved anti-tumor necrosis factor alpha (TNF-α) drug and the world's best-selling anti-inflammatory drug, with global sales in 2020 close to 20 billion U.

Original source: JAMA Dermatology Publishes Data Showing RINVOQ (upadacitinib) Achieved Superiority Versus DUPIXENT (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis